Table 2.
Univariate analysis of factors affecting recurrence within 1 year after curative pancreatectomy for RPC
| Characteristics | REC1 (n = 32)b | Non-REC1 (n = 58)c | P value |
|---|---|---|---|
| Age | 0.6209 | ||
| ≥65 | 25 (78.1%) | 42 (72.4%) | |
| <65 | 7 (21.9%) | 16 (27.6%) | |
| Sex | 0.3859 | ||
| Male | 17 (53.1%) | 25 (43.1%) | |
| Female | 15 (46.9%) | 33 (56.9%) | |
| BMI | 0.86 | ||
| <17 | 3 (9.4%) | 4 (6.9%) | |
| 18–25 | 24 (75%) | 43 (74.1%) | |
| >25 | 5 (15.6%) | 11 (19%) | |
| Location | 0.27 | ||
| Head | 12 (37.5%) | 30 (51.7%) | |
| Body-tail | 20 (62.5%) | 28 (48.3%) | |
| Tumor sizea | 1 | ||
| ≥25 mm | 19 (56.4%) | 34 (58.6%) | |
| <25 mm | 13 (43.6%) | 24 (41.4%) | |
| Histological grade | 0.0158 | ||
| G2–G4 | 31 (96.9%) | 45 (77.6%) | |
| G1 | 1 (3.1%) | 13 (22.4%) | |
| Preoperative SPan-1a | 0.0038 | ||
| ≥35 | 24 (75%) | 24 (41.4%) | |
| <35 | 8 (25%) | 34 (58.6%) | |
| Preoperative CA19-9a | 0.0011 | ||
| ≥529 | 16 (50%) | 9 (15.5%) | |
| <529 | 16 (50%) | 49 (84.5%) | |
| Preoperative CEAa | 0.1616 | ||
| ≥2.4 | 19 (56.4%) | 43 (74.1%) | |
| <2.4 | 13 (43.6%) | 15 (25.9%) | |
| Preoperative Alb | 0.381 | ||
| ≥3.5 | 25 (78.1%) | 50 (86.2%) | |
| <3.5 | 7 (21.9%) | 8 (13.8%) | |
| Preoperative WBCa | 0.1868 | ||
| ≥5400 | 19 (59.4%) | 25 (43.1%) | |
| <5400 | 13 (40.6%) | 33 (56.9%) | |
| Preoperative lymphocytea | 0.3192 | ||
| ≥1023 | 26 (81.3%) | 40 (69.0%) | |
| <1023 | 6 (18.7%) | 18 (31.0%) | |
| Preoperative CRPa | 0.7401 | ||
| ≥2.39 | 3 (9.4%) | 8 (13.8%) | |
| <2.39 | 29 (90.6%) | 50 (86.2%) | |
| mGPS | 0.4168 | ||
| 1–2 | 8 (25%) | 10 (17.2%) | |
| 0 | 24 (75%) | 48 (82.8%) | |
| Adjuvant therapy | 0.4251 | ||
| Yes | 27 (84.4%) | 44 (75.9%) | |
| No | 5 (15.6%) | 14 (24.1%) |
BMI body mass index, mGPS modified Glasgow prognostic score
aCutoff value of tumor size, SPan-1, CA19-9, CEA, WBC, lymphocyte, and CRP was set by drawing ROC curve
bRecurrence within 1 year
cRecurrence at more than 1 year after surgery